Literature DB >> 16223887

Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.

Marilyn A Huestis1, Allan Barnes, Michael L Smith.   

Abstract

BACKGROUND: Knowing the time cannabis was last used is important for determining impairment in accident investigations and clinical evaluations. Two models for predicting time of last cannabis use from single plasma cannabinoid concentrations-model I, using Delta(9)-tetrahydrocannabinol (THC), and model II, using the concentration ratio of 11-nor-9-carboxy-THC (THCCOOH) to THC-were developed and validated from controlled drug administration studies. Objectives of the current study were to extend the validation by use of a large number of plasma samples collected after administration of single and multiple doses of THC and to examine the effectiveness of the models at low plasma cannabinoid concentrations.
METHODS: Thirty-eight cannabis users each smoked a 2.64% THC cigarette in the morning, and 30 also smoked a second cigarette in the afternoon. Blood samples (n = 717) were collected at intervals after smoking, and plasma THC and THCCOOH concentrations measured by gas chromatography-mass spectrometry. Predicted times of cannabis smoking, based on each model, were compared with actual smoking times.
RESULTS: The most accurate approach applied a combination of models I and II. For all 717 plasma samples, 99% of predicted times of last use were within the 95% confidence interval, 0.9% were overestimated, and none were underestimated. For 289 plasma samples collected after multiple doses, 97% were correct with no underestimates. All time estimates were correct for 76 plasma samples with THC concentrations between 0.5 and 2 mug/L, a concentration range not previously examined.
CONCLUSIONS: This study extends the validation of the predictive models of time of last cannabis use to include multiple exposures and low THC concentrations. The models provide an objective and validated method for assessing the contribution of cannabis to accidents or clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223887     DOI: 10.1373/clinchem.2005.056838

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  20 in total

1.  Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients.

Authors:  Phillip Olla; Mohd Tazim Ishraque; Stephen Bartol
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  Ultra-high performance liquid chromatography tandem mass-spectrometry for simple and simultaneous quantification of cannabinoids.

Authors:  Rohitash Jamwal; Ariel R Topletz; Bharat Ramratnam; Fatemeh Akhlaghi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-02-06       Impact factor: 3.205

4.  The Genetics, Neurogenetics and Pharmacogenetics of Addiction.

Authors:  Catherine H Demers; Ryan Bogdan; Arpana Agrawal
Journal:  Curr Behav Neurosci Rep       Date:  2014-03-01

5.  Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration.

Authors:  Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn
Journal:  Br J Clin Pharmacol       Date:  2020-01-20       Impact factor: 4.335

6.  Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).

Authors:  Michael G Holland; David M Schwope; Robert Stoppacher; Shane B Gillen; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2011-07-20       Impact factor: 2.395

7.  Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

Authors:  Erin L Karschner; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-03-29       Impact factor: 4.492

8.  Cannabis, possible cardiac deaths and the coroner in Ireland.

Authors:  W P Tormey
Journal:  Ir J Med Sci       Date:  2012-01-10       Impact factor: 1.568

9.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

10.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.